Furthermore, in stage II and III CRC patients, the sensitivity of our methylation model was over fourfold and twofold higher than the assessment of the CEA level (93.75% vs. 20% and 88% vs. 34%) and over twofold higher than assessment of both the CEA and CA199 levels (93.75% vs. 40% and 88% vs. 42%). Here, CEACAM5 is linked to colorectal carcinoma.